HRT Financial’s Cabaletta Bio CABA Stock Holding History

HRT Financial’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-33,104	Closed	-$109K	–	4278
2026 Q1	$89K	Buy	+33,104	New	+$91.9K	﹤0.01%	3369
2025 Q3	–	Sell	-124,395	Closed	-$189K	–	2906
2025 Q2	$189K	Buy	+124,395	New	+$194K	﹤0.01%	2092
2025 Q1	–	Sell	-18,527	Closed	-$42K	–	2583
2024 Q4	$42K	Buy	+18,527	New	+$65K	﹤0.01%	2127
2024 Q1	–	Sell	-13,958	Closed	-$316K	–	2377
2023 Q4	$316K	Buy	+13,958	New	+$235K	﹤0.01%	1602
2023 Q2	–	Sell	-100,224	Closed	-$828K	–	2524
2023 Q1	$828K	Buy	+100,224	New	+$938K	0.01%	1049
2021 Q4	–	Sell	-25,318	Closed	-$307K	–	3250
2021 Q3	$307K	Sell	25,318 -12,053	-32%	-$111K	﹤0.01%	2392
2021 Q2	$321K	Buy	+37,371	New	+$367K	﹤0.01%	2098

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HRT Financial's CABA Position: Q2 2026 in Review

HRT Financial sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 33,104 shares — an estimated $109K sold.

HRT Financial first reported a position in CABA in Q2 2021 and held it in 7 quarters. The position peaked at $828K in Q1 2023. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

HRT Financial reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 33,104 Cabaletta Bio shares in Q2 2026, an estimated $109K.
HRT Financial first reported a position in Cabaletta Bio in Q2 2021 and held it in 7 quarters.
HRT Financial's Cabaletta Bio position peaked at $828K in Q1 2023.
139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.